NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only
 

Zidovudine 800 mg or zidovudine 500 mg in combination with acyclovir for treatment of HIV-infection.

Jahn S, Busch HW, Reichelt D, Gillessen A, Hoffmann U, Christensen ST, Zidek W; International Conference on AIDS.

Int Conf AIDS. 1993 Jun 6-11; 9: 489 (abstract no. PO-B26-2122).

Medizinische Klinik und Poliklinik, Westfalischen Wilhelms-Universitat Munster, Germany.

OBJECTIVE: We have reported earlier that a combination therapy with AZT 800 mg/d and ACV 800 mg/d reduces the risk of developing infections with HSV, EBV and VZV in ARC and AIDS-patients. To determine if patients on AZT 800 mg/d or 500 mg/d in combination with ACV 800 mg/d survive longer or progress slower than patients on AZT 800 mg/d or 500 mg/d alone. METHODS: The CD4 counts of 408 patients treated between January 1988 and February 1993 were analyzed. At baseline 77 patients had CD4 counts < 150, 70 patients between 150-300, 130 patients between 301-500 and 131 patients > 500. All CD4 counts were measured in the same laboratory. (A) 64 patients (mean CD4 at baseline = 559) received no therapy. (B) 8 patients received ACV 800 mg/d alone (mean CD4 = 582). (C) 71 patients received AZT 500 mg/d (mean CD4 = 374). (D) 83 patients received AZT 800 mg/d (mean CD4 = 453). (E) 86 patients received AZT 500 mg/d and ACV 800 mg/d (mean CD4 = 262). (F) 96 patients received AZT 800 mg/d and ACV 800 mg/d (mean CD4 = 247). RESULTS: After 62 months 123 patients had died (A = 13, B = 3, C = 17, D = 21, E = 34, F = 37). The mean CD4 counts at baseline in these patients were 223 (range 7 to 521). 285 patients were alive. The mean CD4 counts in these patients after 62 months were (A) 218, (B) 244, (C) 176, (D) 221, (E) 178, (F) 163. The frequency of herpesvirus infections (except CMV) was (A) 42%, (B) 25%, (C) 33%, (D) 31%, (E) 11%, (F) 13%. CONCLUSIONS: A combination therapy seems to reduce the progress of HIV-infection and the incidence of herpesvirus infections (except CMV). There is no significant difference between AZT 800 mg/d and AZT 500 mg/d in combination with ACV 800 mg/d.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Acyclovir
  • Antigens, CD4
  • CD4 Lymphocyte Count
  • Drug Therapy, Combination
  • HIV Infections
  • Humans
  • Incidence
  • Zidovudine
  • drug therapy
  • immunology
  • therapy
Other ID:
  • 93335738
UI: 102205116

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov